Recently, starting from the ATN-291 antibody, Weifei Lu and collaborators, developed the ATN-291 F(ab′)2 which retained the selectivity and specificity for uPA in MDA-MB-231 breast cancer cells, compared with the entire ATN-291. Here, PLAU is linked to breast carcinoma.